# Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence

> **NCT04663100** · NA · UNKNOWN · sponsor: **University of Tennessee** · enrollment: 30 (estimated)

## Conditions studied

- Chronic Myeloid Leukemia
- Chronic Lymphocytic Leukemia
- Multiple Myeloma
- Multiple Chronic Conditions

## Interventions

- **OTHER:** Patient-reported outcome measure
- **OTHER:** Comprehensive Medication Review
- **OTHER:** Pharmacist communication

## Key facts

- **NCT ID:** NCT04663100
- **Lead sponsor:** University of Tennessee
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-08
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-12-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04663100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04663100, "Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04663100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*